Clinical trials: HPV InfectioN
Infections, Papillomavirus, Papillomavirus Vaccines
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00359619
- Testing
- CervarixTM, HPV investigational vaccine GSK568893A, different formulations
- Where
- 10 sites in United States, Belgium
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is…
- Trial name
- NCT00652938
- Testing
- HPV Vaccine (GSK580299) Cervarix TM, Engerix B
- Where
- 7 sites in Netherlands, Sweden
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer.
- Trial name
- NCT00604175
- Testing
- Quadrivalent HPV vaccine
- Where
- 61 sites in United States, Brazil and 2 more
- Volunteers
- 319 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
This study has been designed to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine when administered according to alternative 2-dose schedules (0,6 months and 0,12 months) in healthy 9-14 year old…
- Trial name
- NCT01381575
- Testing
- GSK Biologicals' HPV vaccine 580299
- Where
- 33 sites in Canada, Germany and 3 more
- Volunteers
- 1,447 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Warts, Human Papilloma Virus
Candin Safety & Efficacy Study for the Treatment of Warts
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
- Trial name
- NCT01757392
- Testing
- Candida albicans Skin Test Antigen
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Nielsen BioSciences, Inc.
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the 580299 HPV vaccine up to 10 years…
- Trial name
- NCT00877877
- Testing
- Blood sampling
- Where
- 26 sites in Colombia, Germany and 3 more
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus (HPV) Infection
GARDASIL Reexamination Study (V501-059)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting…
- Trial name
- NCT01062074
- Volunteers
- 3,605 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV…
- Trial name
- NCT00937950
- Testing
- Gynaecological follow-up
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 2,022 people
- Sponsor
- GlaxoSmithKline
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose.
- Trial name
- NCT03912831
- Testing
- KITE-439, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- Gilead Sciences
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Genital Warts, Perianal Warts
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
- Trial name
- NCT02462187
- Testing
- NVN1000 8% Gel, NVN1000 16%, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novan, Inc.
Human Papilloma Virus, Hiv
Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Patients with immunodeficiencies are at increased risk of developing persistent HPV infection and as such HPV-related disease (genital warts and cancer).
- Conditions
- Human Papilloma Virus, Hiv, Organ Transplants
- Trial name
- NCT03525210
- Testing
- 9-valent HPV vaccine
- Where
- Belgium
- Volunteers
- 271 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT01932697
- Testing
- Docetaxel, Hyperfractionation, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Infection
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age.
- Trial name
- NCT01984697
- Testing
- V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
- Volunteers
- 1,518 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts, Plantar Wart
Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.
The principal aim of this study is to evaluate the efficacy and the safety of the tested product on common and plantar wart after 35 days of treatment.
- Conditions
- Warts, Plantar Wart, Common Wart
- Trial name
- NCT06214559
- Testing
- Sérum VERRUPRO
- Where
- 2 sites in Tunisia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Swiss Footcare Laboratories - Poderm Professional
HIV Positive, Anal Condylomata
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
The primary objective of this pilot study is to evaluate the effect of the HPV vaccine Gardasil on anal condylomata recurrence and persistence rates in HIV positive patients.
- Conditions
- HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
- Trial name
- NCT00941889
- Testing
- Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
Cervical Cancer, Papillomavirus Infection
HPV Self-Sampling in Somali Women (Isbaar Project)
This study plans to assess the effect of implementing HPV self-sampling in primary care on uptake of cervical cancer screening in 30-65 year old Somali women who are due for cervical cancer screening.
- Conditions
- Cervical Cancer, Papillomavirus Infection, Uterine Diseases, Uterine Cervical Disease
- Trial name
- Isbaar (NCT05453006)
- Testing
- COPAN 552c.80 FLOQSwab
- Where
- United States
- Volunteers
- 3,367 people
- Sponsor
- University of Minnesota
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC